FFAR4: A New Player in Cardiometabolic Disease?

Area of Science:

• Molecular biology and metabolic disease research.
• G protein-coupled receptor (GPCR) signaling pathways.
• Cardiovascular disease (CVD) and atherosclerosis research.

Background:

• Free fatty acids (FFAs) are key players in metabolic diseases like obesity, type 2 diabetes mellitus, and CVD.
• Free fatty acid receptors (FFARs), including FFAR4 (GPR120), are GPCRs crucial for energy homeostasis.
• FFAR4 is highly expressed in adipocytes, endothelial cells, and macrophages, regulating adipogenesis, insulin sensitivity, and inflammation.

Purpose of the Study:

• To review the established role of FFAR4 in metabolic diseases.
• To highlight the underappreciated role of FFAR4 in atherosclerosis and CVD development.
• To consolidate current understanding of FFAR4's therapeutic potential.

Main Methods:

• Literature review of studies on FFAR4 function in metabolic and cardiovascular contexts.
• Analysis of FFAR4's impact on cellular processes relevant to metabolic homeostasis and atherosclerosis.
• Synthesis of findings from human and mouse models.

Main Results:

• FFAR4 activation improves insulin sensitivity, adipogenesis, and reduces inflammation.
• FFAR4 dysfunction is linked to insulin resistance, obesity, and cardiac remodeling.
• FFAR4 activation demonstrates cardioprotective effects by reducing monocyte-endothelial cell interactions, enhancing cholesterol efflux, and decreasing lesion size.

Conclusions:

• FFAR4 is a critical regulator of metabolic homeostasis and a potential therapeutic target for obesity and diabetes.
• Emerging evidence strongly implicates FFAR4 in mitigating atherosclerosis and CVD.
• Targeting FFAR4 presents a promising strategy for treating a spectrum of metabolic and cardiovascular diseases.